The renal profile of eprosartan

Pharmacotherapy

Volumn 19, Issue 4 II, 1999, Pages

  Sica, Domenic A ^a   Hollenberg, Norman K ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; RENIN; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; REVIEW; SODIUM INTAKE; SODIUM RETENTION;

EID: 0032899205     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.7.86s.30949     Document Type: Review

References (42)

1. Sica DA. Kinetics of angiotensin-converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992;20(suppl 10):S13-20.
2. Sica DA, Cutler RE, Parmer RJ, et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril, and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991;20:420-7.
3. de Zeeuw D, Remuzzi G, Kirch W. The pharmacokinetics of candesartan cilexitil in patients with renal or hepatic impairment. J Hum Hypertens 1997;11(suppl 2):S37-42.
4. Sica DA, Shaw WC, Lo MW, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995;13(suppl 1):S49-52.
5. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997;62:610-18.
6. 1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1997;63:471-81.
7. Price DA, De'Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997;30:240-6.
8. Goldberg MG, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13.
9. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.
10. Carr AA, Prisant LM. Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 1996;36:3-12.
11. Larochelle P, Flack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997;80:1613-15.
12. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.
13. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-50.
14. Sica DA, Deedwania PC. Cardiorenal implications of angiotensin-receptor antagonist therapy. Congest Heart Fail 1998;4:35-40.
15. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1-29.
16. Oddou-Stock P, Gatlin M, Kobi P, et al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension. Am J Hypertens 1997;10:84A.
17. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53.
18. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther 1998;20:398-409.
19. Chapelsky M, Martin DE, Tenero DM, et al. A dose proportionality study of eprosartan in healthy male volunteers J Clin Pharmacol 1998;38:34-9.
20. Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55: 244-51.
21. White WB, McCabe EJ, Mansoor GA. Comparison of office and ambulatory blood pressure measurements to assess the angiotensin II receptor antagonist eprosartan. Blood Press Monit 1996;1:45-50.
22. Edwards RM, Aiyar N, Ohlstein EH, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260: 175-81.
23. Martin DE, Chapelsky M, Ilson BE, et al. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol 1998;38:129-37.
24. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimizing renal and extrarenal toxicity. Drug Saf 1997;16:205-31.
25. Gehr TWB, Sica DA, Duchin K, Grasella D. Fosinopril pharmacokinetics and pharmacodynamics in maintenance hemodialysis. Eur J Clin Pharmacol 1993;45:431-6.
26. Sica DA, Schoolwerth A. Renal handling of organic anions and cations and excretion of uric acid. In: Brenner BM, Rector FC, eds. The kidney, 6th ed. Philadelphia: WB Saunders, 1996:607.
27. Kovacs SJ, Tenero DM, Martin DE, Ilson BE, Jorkasky DK. The pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Pharmacotherapy In press.
28. Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.
29. Sica DA, Ripley E. Angiotensin-converting enzyme inhibitors. In: Izzo JL, Black HR, eds. Hypertension primer, 2nd ed. Philadelphia: Williams & Wilkins, 1998:372-6.
30. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens 1987;9:243-59.
31. Hajj-Ali AF, Zimmerman BG. Kinin contribution to renal vasodilator effect of captopril in rabbit. Hypertension 1991;17:504-9.
32. Sica DA, Deedwania PC. Renal considerations in the use of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Congest Heart Fail 1997;3:54-9.
33. Ichikawa I, Yoshioka T, Fogo A, Kon V. Role of angiotensin II in altered glomerular hemodynamics in congestive heart failure. Kidney Int 1990;38(suppl 30):S123-6.
34. Ritter JM, Cockcroft JR, Sciberras DG, et al. Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature. J Hypertens 1993;11(suppl 3):S59-61.
35. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER and angiotensin converting enzyme inhibitors for the treatment of essential hypertension. Am J Cardiol 1995;75:793-5.
36. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 1997;30:983-91.
37. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
38. Gandhi SK, Gainer J, King D, Brown NJ. Gender affects renal vasoconstrictor response to angiotensin-I and angiotensin-II. Hypertension 1998;31:90-6.
39. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
40. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
41. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system: is angiotensin-converting enzyme inhibition the last word? Hypertension 1995;26:602-9.
42. SmithKline Beecham Pharmaceuticals. Data on file. King of Prussia, PA.